Universal Beteiligungs und Servicegesellschaft mbH Invests $1.09 Million in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 20,141 shares of the company's stock, valued at approximately $1,091,000.

A number of other institutional investors have also bought and sold shares of the company. Deutsche Bank AG raised its position in shares of MoonLake Immunotherapeutics by 59.8% in the 4th quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after acquiring an additional 338 shares in the last quarter. Birchview Capital LP bought a new stake in MoonLake Immunotherapeutics in the fourth quarter worth approximately $217,000. KLP Kapitalforvaltning AS bought a new stake in MoonLake Immunotherapeutics in the fourth quarter worth approximately $244,000. PEAK6 LLC acquired a new position in MoonLake Immunotherapeutics in the fourth quarter valued at approximately $271,000. Finally, Mariner LLC bought a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth approximately $272,000. Institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Stock Performance

MLTX traded down $2.22 during midday trading on Thursday, reaching $48.83. 1,381,442 shares of the company were exchanged, compared to its average volume of 376,008. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -37.85 and a beta of 1.31. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $58.26. The company's fifty day moving average price is $38.74 and its 200 day moving average price is $43.93.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same period in the previous year, the firm posted ($0.22) EPS. As a group, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MLTX has been the subject of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Wedbush reiterated an "outperform" rating and set a $80.00 price objective (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Royal Bank of Canada reissued an "outperform" rating and set a $67.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday. The Goldman Sachs Group decreased their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $78.71.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.